Company news
Arvinas, Inc. news in 2024
Arvinas, Inc.'s news releases, calls and decks from 2024, newest first.
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
December 9, 2024
Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium
November 24, 2024
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
October 29, 2024
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day
October 21, 2024
Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024
October 20, 2024
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
July 29, 2024
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
June 23, 2024
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
June 20, 2024
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
June 16, 2024
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
May 22, 2024
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
May 15, 2024
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
May 8, 2024
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 6, 2024
Arvinas to Present at Upcoming Investor Conferences
May 1, 2024
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
April 23, 2024
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
April 10, 2024
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
March 17, 2024
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 26, 2024
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
February 19, 2024
Arvinas Announces Chief Financial Officer Transition
February 19, 2024
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
February 5, 2024
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
January 31, 2024
Arvinas Appoints Jared Freedberg as General Counsel
January 15, 2024
Calls in 2024
Decks in 2024
- Stifel Webinar (February 2024)
Conference · 15 slides · Feb 14, 2024